Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | MMP14 | P50281 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.30 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23983434 | 0.89 | ELANE (0.32) | MEN1LMNAMAPTMAPK1RECQL | |
| SCHEMBL22652359 | 0.88 | ELANE (0.32) | MEN1LMNAMAPTMAPK1RECQL | |
| SCHEMBL23129066 | 0.87 | ELANE (0.31) | ELANE | |
| SCHEMBL16905742 | 0.86 | KDM4E (0.35) | LMNAMAPTMAPK1KMT2ANPSR1 | |
| SCHEMBL22652454 | 0.86 | ELANE (0.31) | ELANE | |
| SCHEMBL18961930 | 0.86 | TNKS (0.30) | — | |
| SCHEMBL19246582 | 0.86 | L3MBTL1 (0.38) | MEN1MAPTMAPK1KMT2ANPSR1 | |
| SCHEMBL18961945 | 0.86 | KDM4E (0.31) | MAPTNPSR1ELANE | |
| SCHEMBL22223548 | 0.85 | MEN1 (0.35) | MEN1LMNAMAPTMAPK1RECQL | |
| SCHEMBL22211923 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11706981-B2 | Organic light emitting device and compounds for use in same | IDEMITSU KOSAN CO., LTD. (JP) | 2023-07-18 | — | — | US | disclosed |
| US-11706981-B2 | Organic light emitting device and compounds for use in same | IDEMITSU KOSAN CO., LTD. (JP) | 2023-07-18 | — | — | US | disclosed |
| US-20200227652-A1 | ORGANIC LIGHT EMITTING DEVICE AND COMPOUNDS FOR USE IN SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11706981-B2 | Organic light emitting device and compounds for use in same | SLCO4C1, XPO6, ERCC1 | MEN1 544/4885LMNA 1402/4885MAPT 485/4885 |
| US-20200227652-A1 | ORGANIC LIGHT EMITTING DEVICE AND COMPOUNDS FOR USE IN SAME | SLCO4C1, XPO6, ERCC1 | MEN1 544/4885LMNA 1402/4885MAPT 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.